AstraZeneca invests in US oral biologics firm Rani Therapeutics
The latest round of funding brings Rani Therapeutics’ total investment to over $70m. Other investors in the round were Virtus Inspire Ventures and Ping An Ventures. The company’s
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
At Week 48, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens, based on percentages of patients with HIV-1 RNA levels less than 50
Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties.